Homology Medicines (STU:35H) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Homology Medicines FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Homology Medicines's Free Cash Flow for the three months ended in Dec. 2023 was €-19.78 Mil. Homology Medicines's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Homology Medicines's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Homology Medicines's current FCF Yield % is -3,195.03%.

The historical rank and industry rank for Homology Medicines's FCF Margin % or its related term are showing as below:

STU:35H' s FCF Margin % Range Over the Past 10 Years
Min: -8344.12 Med: -3606.23 Max: -330.13
Current: -8321.47

During the past 8 years, the highest FCF Margin % of Homology Medicines was -330.13%. The lowest was -8344.12%. And the median was -3606.23%.

STU:35H's FCF Margin % is ranked worse than
90.91% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs STU:35H: -8321.47

Homology Medicines FCF Margin % Historical Data

The historical data trend for Homology Medicines's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines FCF Margin % Chart

Homology Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-6,796.00

-3,629.45

-330.13

-3,583.52

-8,344.53

Homology Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-3,392.87	-3,277.30	-6,678.29	-	-

Competitive Comparison of Homology Medicines's FCF Margin %

For the Biotechnology subindustry, Homology Medicines's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Homology Medicines's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Homology Medicines's FCF Margin % falls into.

Homology Medicines FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Homology Medicines's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-88.452	/	1.06
	=	-8,344.53 %

Homology Medicines's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-19.784	/	0
	=	%

Homology Medicines FCF Margin % Related Terms

Thank you for viewing the detailed overview of Homology Medicines's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (STU:35H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

FIXX:USA

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (STU:35H) Headlines

No Headlines